Abstract
Development of type 1 diabetes mellitus (T1DM) has been reported in patients receiving interferon (IFN) therapy for hepatitis C virus (HCV) infection. We studied two patients with chronic HCV infection who had an anti-glutamic acid decarboxylase antibody (GAD-ab) before IFN therapy. Their blood sugar and GAD-ab levels were monitored during IFN therapy. Case 1 was a 61-year-old man with 16.9 U/mL of GAD-ab. The GAD-ab level decreased during IFN therapy, but remained positive. Case 2 was a 65-year-old woman with 2.0 U/mL of GAD-ab. Her GAD-ab level increased during IFN therapy, but decreased after withdrawal of IFN. Insulin secretion in both patients was kept within physiologically normal range during IFN therapy, and the treatment was completed without developing T1DM in both cases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
